Crism Therapeutics Corp - Pharmaceutical company headquartered in Surrey - Begins first day of trading on AIM. On Wednesday, Crism changed its name from Amur Minerals Corp, after purchasing Extruded Pharmaceuticals Ltd and exiting its mineral exploration business.
The company, now Crism, has created ChemoSeed, an innovate polymeric delivery system for chemotherapy. It expects to begin its first clinical trial in 2025. The company says Chemoseed’s potential for quick progression to clinical trials would reduce development costs by €400,000.
Crism Chief Operating Officer Andrew Webb commented: ‘We believe Crism has an attractive risk profile owing to using an existing pre-approved drug, irinotecan, and we have a clear strategy for progressing ChemoSeed through development and to commercialisation.’
Copyright 2024 Alliance News Ltd. All Rights Reserved.
